Business Context and Reporting Period
Company: MediciNova, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Business Stage: Development-stage biopharmaceutical company.
Operations: The company focuses on acquiring and developing novel small molecule therapeutics, primarily through strategic alliances with Japanese pharmaceutical companies. It has no approved products for commercial sale and generates no product revenue. Operations are funded by equity sales and investment income.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2008 | Balance Sheet (Sep 30, 2008) |
|---|---|---|---|
| Revenues | $0 | $0 | N/A |
| Net Loss | $(4.82) million | $(20.51) million | N/A |
| Operating Expenses | $5.70 million | $18.82 million | N/A |
| Research & Development | $3.50 million | $11.82 million | N/A |
| Cash and Cash Equivalents | N/A | N/A | $23.08 million |
| Marketable Securities (Current) | N/A | N/A | $24.37 million |
| Total Assets | N/A | N/A | $51.88 million |
| Accumulated Deficit | N/A | N/A | $(225.57) million |
Material Changes vs. Prior Period
- Revenue: No revenue was generated in the current or prior periods. The company ceased generating revenue from development management services in fiscal year 2007.
- Net Loss: Net loss for the nine months ended September 30, 2008, was $20.5 million, a significant decrease from $45.9 million in the same period in 2007. This improvement is primarily due to reduced R&D spending and a reversal of foreign exchange losses.
- R&D Expenses: R&D expenses decreased by $28.9 million (from $40.7 million to $11.8 million) for the nine-month period. This reduction resulted from the termination of the Phase III trial for MN-001 (bronchial asthma), the completion of the Phase II trial for MN-166 (Multiple Sclerosis), and the cessation of development for MN-305 and MN-029.
- Impairment Charges: The company recorded a $3.3 million impairment charge on marketable securities (Auction Rate Securities or ARS) during the nine months ended September 30, 2008, due to other-than-temporary declines in fair value caused by the illiquidity of the ARS market. No additional impairment was recorded in the third quarter.
- Foreign Exchange: A $0.5 million reversal of foreign exchange loss was recorded in the third quarter due to the strengthening of the U.S. dollar against the euro, reducing the liability for a clinical trial conducted in Eastern Europe.
Guidance, Outlook, and Risks
- Strategic Focus: Management is prioritizing two product candidates: MN-221 for acute exacerbations of asthma (Phase IIb ongoing) and MN-166 for Multiple Sclerosis (Phase II completed). Further development of MN-166 is paused pending a strategic collaboration for Phase III.
- Liquidity: As of September 30, 2008, the company held approximately $47.5 million in cash, cash equivalents, and current marketable securities. Management believes this is sufficient to fund operations through at least September 30, 2009.
- Auction Rate Securities (ARS) Risk: A significant portion of the company's investments ($24.4 million current, $2.9 million long-term) are in ARS, which have failed to auction due to credit market turmoil. While a brokerage firm has offered to repurchase these securities at par starting June 30, 2010, and offered a loan program, there is no assurance these arrangements will be funded or that liquidity will return to the market.
- Capital Needs: The company expects to incur substantial net losses for the foreseeable future and will require additional financing to fund clinical trials and operations. Failure to secure capital could force the delay or termination of development programs.
- Regulatory Risks: Success depends on obtaining FDA approval for MN-221 and MN-166. Clinical trials are costly, time-consuming, and subject to failure or delays.
Investor Verification Checklist
- ARS Liquidity Status: Verify the current status of the "ARS Rights Offer" and the "ARS loan" program with the brokerage firm to assess the risk of capital being trapped in illiquid securities.
- Cash Runway: Confirm the company's burn rate and whether the projected runway through September 2009 remains valid given current market conditions.
- Collaboration for MN-166: Monitor for announcements regarding a strategic partner for MN-166, as further development is contingent on this partnership.
- Phase IIb Enrollment: Track enrollment progress for the MN-221 Phase IIb trial, which was noted as slower than anticipated.
- Patent Expirations: Review the patent landscape for MN-166, noting the lack of unqualified composition of matter claims and potential competition from Avigen, Inc.